Like most websites The Translational Scientist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Disease Area Biomedical engineering, Infectious diseases

Rescinding Antimicrobial Resistance

Klebsiella pneumoniae is probably the most threatening superbug, and a major cause of treatment failure and mortality associated with hospital infections worldwide,” says Luca Guardabassi, a professor of clinical microbiology at Ross University School of Veterinary Medicine in the West Indies. The emergence of superbugs – microbes resistant to a multitude of drugs – has spurred many researchers to explore drugs with greater potency. But the team led by Guardabassi decided to tackle the problem from the other side of the fence – by reversing antimicrobial resistance (1).

To reach that ambitious goal, they used next generation sequencing (NGS) to construct a transposon library of the bacterium containing over 430,000 unique insertions, which led them to find chromosomal genes that are essential for growth during antimicrobial exposure – collectively dubbed “the secondary resistome”.

How can these findings reverse antimicrobial resistance? The team proposed that inactivation of the secondary resistome using “helper drugs” (non-therapeutic compounds administered alongside drugs to boost potency) could ‘restore’ antibiotic susceptibility in K. pneumoniae. They’ve already identified a plethora of genes and metabolic pathways in the secondary resistome that have the potential for helper drug targeting, but the team is still “far away from clinical applications,” according to Guardabassi. “To translate our findings into clinical practice, we need to take a further step from the antimicrobial helper drug targets that we have identified, and develop helper drugs interfering with such targets. There is still a long way to go, but I am determined to use the rest of my career to accomplish this goal.”

With that goal in mind, Guardabassi and his team have set the next phase of research into motion. “We have prepared a NIH grant proposal to help us generate a catalogue of antimicrobial helper drug target candidates for all main antimicrobial classes, using the same NGS-based approach we employed in K. pneumoniae.” To date, the team has identified two potential drug helpers – one anti-inflammatory and one anti-fungal – which they hope to use to generate an in vivo mouse model.

Enjoy our FREE content!

Log in or register to gain full unlimited access to all content on the The Translational Scientist site. It’s FREE and always will be!


Or register now - it’s free and always will be!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts

Or Login via Social Media

By clicking on any of the above social media links, you are agreeing to our Privacy Notice.

  1. B Jana et al., “The secondary resistome of multidrug-resistant Klebsiella pneumoniae”, Sci Rep, 7, (2017). PMID: 28198411.

About the Author

William Aryitey

My fascination with science, gaming, and writing led to my studying biology at university, while simultaneously working as an online games journalist. After university, I travelled across Europe, working on a novel and developing a game, before finding my way to Texere. As Associate Editor, I’m evolving my loves of science and writing, while continuing to pursue my passion for gaming and creative writing in a personal capacity.

Register to The Translational Scientist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts